PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon

PITUItary Carcinomas or Aggressive Tumors REgistry: Monocentric Study Form a Cohort of Patient Operated on for Pituitary Tumors in University Hospital of Lyon (France)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02854228

Acronym

PITUICARE-Lyon

Enrollment

1300

Registered

2016-08-03

Start date

2007-02-28

Completion date

2020-12-31

Last updated

2016-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary Tumor

Keywords

Pituitary tumor, pituitary carcinoma, acromegaly, cushing, prolactinoma

Brief summary

The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions of all types.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

• patients with confirmed pituitary disease

Exclusion criteria

• patients who do not have confirmed pituitary disease

Design outcomes

Primary

Measure	Time frame	Description
Progression free survival after pituitary surgery according to the clinicopathological classification (HYPOPRONOS)	up to 10 years (postoperatively)	Clinical, biochemical et imaging evaluation of a cohort of patient operated in the referral center for pituitary tumor. Identification of recurrence or progression an analysis of the clinicopathological classification. Evaluation of the different therapeutic strategies (med, surgery, chemotherapies, radiation therapy) to prevent recurrence or tumor progression.

Secondary

Measure	Time frame	Description
Correlation between percentage of SSTR expression of the pituitary tumor and somatostatine analogs efficacy.	2007-2020	Analysis of the expression of SST receptors in GH, PRL and ACTH secreting pituitary tumors: SSTR expression accessed by immunohistochemistry of the pituitary tumor. Evaluation of the response to somatostatine analogs: somatostatine analogs efficacy evaluated by normalization of hormone hypersecretion in ACTH, GH and PRL secreting pituitary tumor.
Correlation between percentage of MGMT expression of the pituitary tumor and tumor response to temozolomide.	2007-2020	Evaluation of MGMT expression (accessed by immunohistochemistry of the pituitary tumor) and response to temozolomide treatment (evaluated according to RECIST criteria) for patient presenting multirecurrent tumors resistant to conventional treatment.

Countries

France

Contacts

Primary ContactGerald Raverot, MD PhD

gerald.raverot@chu-lyon.fr(0)472119325

Backup ContactEmmanuel Jouanneau, MD PhD

emmanuel.jouanneau@chu-lyon.fr(0)472357411

Outcome results